- See the Partnerships page for details on relationships between larger pharma companies and biotech companies I follow, along with links to pipeline charts, conference call transcripts, and my notes.
GlaxoSmithKline $GSK
- Promacta (licensed from Ligand LGND) phase 3 HCV data is "in house and being reviewed" - first trial being presented at AASLD this week and we will find out 11/7/2011 if the second trial will be presented at ASH.
- promacta program in chronic liver disease - listed as ready for phase 3, but awaiting full HCV data before deciding next steps
- ISIS-partnered drug still listed in phase 2 - is not one of the 2 programs that will move into phase 3 by end of 2011.
- Transcript Link.
- "we have been missing an important undisclosed launch due to timing of FDA approval. We are hopeful that this product will be launched in Q4" [Per their statements, this product could contribute about $0.10 per share or $90m profit in 4q2011. Reports (see here and here) indicate that this refers to generic Lipitor and the possibility to striking a deal to utilize Ranbaxy's 180-day exlcusivity period]
- Re Lovenox generic "we have no update"
- Transcript Link.
- "Worth mentioning also that we have launched a authorized generic of Lovenox in the United States, due to the fact that there was...appearance of another generic coming from a competitor, as you’re probably aware. The generic had to be withdrawn by a decision of U.S. District Court. We maintain, of course, our authorized generic on the market. And once again, we are overall rather content with the performance of Lovenox inside the competitive environment now in the United States. We believe that so far, we have taken the right decisions, and we of course intend to continue to do so also with our authorized generic."
- On your enoxaparin generic, now that Watson’s off the market for the time being, can you actually take that authorized generic off the market, and would there be any merit in doing so? "Yes. That’s an easy one. For the time being, at least, we have no intention to take it off the market. We believe it’s an interesting part of our overall strategy, that this is a market which de facto is split between, let’s make it simple, the retailer and the hospital market. And we believe it is good to have various options with different pricing. So we have not at all any intention today to discontinue the generic"